[144] STERIS plc SEC Filing

Rhea-AI Filing Summary

STERIS plc (STE)5,036 ordinary shares. The planned sale, through Charles Schwab & Co., Inc., has an aggregate market value of $1,297,033 and is expected to occur around 11/18/2025 on the NYSE. The company reports 98,147,009 shares outstanding, so this planned sale represents a small portion of total shares.

The securities to be sold were acquired mainly through equity compensation from STERIS plc, including an employee stock option exercise of 3,536 shares on 11/18/2025 via a broker-assisted cashless exercise and several restricted stock lapses between 05/31/2023 and 10/01/2024. The notice also reports that the same holder sold 3,204 shares of STERIS on 08/20/2025 for gross proceeds of $798,560 in the past three months.

11/18/2025 - 04:46 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	5036	1297033.00	98147009	11/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	11/18/2025	Employee Stock Option Exercise	STERIS plc			3536	11/18/2025	Broker Payment for Cashless Exercise
Ordinary	05/31/2023	Restricted Stock Lapse	STERIS plc			242	05/31/2023	Equity Compensation
Ordinary	05/31/2024	Restricted Stock Lapse	STERIS plc			169	05/31/2024	Equity Compensation
Ordinary	06/03/2024	Restricted Stock Lapse	STERIS plc			909	06/03/2024	Equity Compensation
Ordinary	10/01/2024	Restricted Stock Lapse	STERIS plc			180	10/01/2024	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Renato Tamaro 70 SIR JOHN ROGERSON'S QUAY DUBLIN L2 D02 R296	STERIS plc	08/20/2025	3204	798560.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)